Federico Caobelli1, Pierpaolo Alongi2,3, Laura Evangelista4, Maria Picchio5, Giorgio Saladini4, Marco Rensi6, Onelio Geatti6, Angelo Castello7, Iashar Laghai7, Cristina E Popescu8, Carlotta Dolci9, Cinzia Crivellaro9, Silvia Seghezzi10, Margarita Kirienko11, Vincenzo De Biasi12, Fabrizio Cocciolillo13, Natale Quartuccio14. 1. Klinik für Nuklearmedizin, Medizinische Hochschule Hannover, Hanover, Germany. 2. Nuclear Medicine Unit, University of Milano-Bicocca, Piazza dell'Ateneo Nuovo 1, Milan, 20126, Italy. alongi.pierpaolo@hsr.it. 3. Nuclear Medicine Department, IRCSS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. alongi.pierpaolo@hsr.it. 4. Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. 5. Nuclear Medicine Department, IRCSS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. 6. Nuclear Medicine Department, Hospital of Udine, Udine, Italy. 7. Nuclear Medicine Department, University of Florence, Florence, Italy. 8. Nuclear Medicine Department, Niguarda Ca' Granda Hospital, Milan, Italy. 9. Nuclear Medicine Department; San Gerardo Hospital, Tecnomed Foundation, University of Milan-Bicocca, Milan, Italy. 10. Nuclear Medicine Department, Hospital of Treviglio, Treviglio, Bergamo, Italy. 11. Nuclear Medicine Unit, University of Milano-Bicocca, Piazza dell'Ateneo Nuovo 1, Milan, 20126, Italy. 12. Nuclear Medicine Department, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. 13. Nuclear Medicine Department, Catholic University of the Sacred Heart, Rome, Italy. 14. Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphological and Functional Images, University of Messina, Messina, Italy.
Abstract
PURPOSE: Ovarian cancer is the eighth most common malignancy among women and has a high mortality rate. Prognostic factors able to drive an effective therapy are essential. (18)F-Fluoro-2-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) has been investigated in patients with epithelial ovarian cancer and showed promise in diagnosing, staging, detecting recurrent lesions and monitoring treatment response. Conversely, its prognostic role remains unclear. We aimed at assessing the prognostic value of (18)F-FDG PET/CT performed in the restaging process in a multicentre study. METHODS: We evaluated 168 patients affected by ovarian carcinoma, who underwent a restaging (18)F-FDG PET/CT. The presence of local recurrences, lymph node involvement and distant metastasis was recorded as well as lesion dimensions, maximum and mean standardized uptake values (SUVmax and SUVmean, respectively). Progression-free survival (PFS) and overall survival (OS) at 3 and 4 years were computed by using Kaplan-Meier curves. Increased odds ratio was assessed using Cox regression analysis testing all lesion parameters measured by PET/CT. RESULTS: PFS was significantly longer in patients with a negative than a positive restaging PET/CT study (3- and 4-year PFS 64 and 53% vs 23 and 12%, respectively; p < 0.001). Similarly, a negative study was associated with a significantly higher OS rate after 4 years of follow-up (67 vs 25% in negative and positive groups, respectively; p < 0.001). Lymph node or distant involvement were also independently associated with an increased risk of disease progression [hazard ratio (HR) 1.6 and 2.2, respectively; p = 0.003]. Moreover, PET/CT showed an incremental prognostic value compared to the International Federation of Gynecology and Obstetrics (FIGO) staging system. In the analysis of patient subsets, individuals with the same FIGO stage I-II but with negative PET had a significantly better 4-year OS than patients with low FIGO stage but positive PET. This implies that patients with the same FIGO stage can be further prognostically stratified using PET (p = 0.01). At receiver-operating characteristic (ROC) analysis, no thresholds for semiquantitative parameters were predictive of a worse outcome. CONCLUSION: (18)F-FDG PET/CT has an important prognostic value in assessing the risk of disease progression and mortality rate. An efficacious therapy planning might therefore effectively rely on (18)F-FDG PET/CT findings. Semiquantitative data were not proven to be an effective tool to predict disease progression.
PURPOSE:Ovarian cancer is the eighth most common malignancy among women and has a high mortality rate. Prognostic factors able to drive an effective therapy are essential. (18)F-Fluoro-2-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) has been investigated in patients with epithelial ovarian cancer and showed promise in diagnosing, staging, detecting recurrent lesions and monitoring treatment response. Conversely, its prognostic role remains unclear. We aimed at assessing the prognostic value of (18)F-FDG PET/CT performed in the restaging process in a multicentre study. METHODS: We evaluated 168 patients affected by ovarian carcinoma, who underwent a restaging (18)F-FDG PET/CT. The presence of local recurrences, lymph node involvement and distant metastasis was recorded as well as lesion dimensions, maximum and mean standardized uptake values (SUVmax and SUVmean, respectively). Progression-free survival (PFS) and overall survival (OS) at 3 and 4 years were computed by using Kaplan-Meier curves. Increased odds ratio was assessed using Cox regression analysis testing all lesion parameters measured by PET/CT. RESULTS: PFS was significantly longer in patients with a negative than a positive restaging PET/CT study (3- and 4-year PFS 64 and 53% vs 23 and 12%, respectively; p < 0.001). Similarly, a negative study was associated with a significantly higher OS rate after 4 years of follow-up (67 vs 25% in negative and positive groups, respectively; p < 0.001). Lymph node or distant involvement were also independently associated with an increased risk of disease progression [hazard ratio (HR) 1.6 and 2.2, respectively; p = 0.003]. Moreover, PET/CT showed an incremental prognostic value compared to the International Federation of Gynecology and Obstetrics (FIGO) staging system. In the analysis of patient subsets, individuals with the same FIGO stage I-II but with negative PET had a significantly better 4-year OS than patients with low FIGO stage but positive PET. This implies that patients with the same FIGO stage can be further prognostically stratified using PET (p = 0.01). At receiver-operating characteristic (ROC) analysis, no thresholds for semiquantitative parameters were predictive of a worse outcome. CONCLUSION: (18)F-FDG PET/CT has an important prognostic value in assessing the risk of disease progression and mortality rate. An efficacious therapy planning might therefore effectively rely on (18)F-FDG PET/CT findings. Semiquantitative data were not proven to be an effective tool to predict disease progression.
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: M Murakami; T Miyamoto; T Iida; H Tsukada; M Watanabe; M Shida; H Maeda; S Nasu; S Yasuda; M Yasuda; M Ide Journal: Int J Gynecol Cancer Date: 2006 Jan-Feb Impact factor: 3.437
Authors: Ahmed Ebada Salem; Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Richard H Wiggins; John M Hoffman; Kathryn A Morton Journal: Cancers (Basel) Date: 2022-06-18 Impact factor: 6.575